NAOR
Decentralized Rapid RNA Diagnostic Solutions
Company Overview
Snapshot
Founded in July 2020, NAOR operates with 1–10 employees. The company has completed 2 funding rounds and, as of March 2024, has ceased operations.
Business overview
NAOR develops a platform for rapid RNA diagnosis of pathogens like COVID-19, leveraging a one-step nucleic acid amplification method for high sensitivity and specificity. Its technology combines biochemistry, electronics, and artificial intelligence to deliver lab-grade results in diverse field settings, including airports, schools, and workplaces, with potential for at-home testing. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Digital Medical Diagnostics.
Strategic signal
NAOR ceased operations in March 2024, indicating a significant shift in its corporate trajectory. This development signals to investors and innovation teams that the company is no longer actively pursuing its decentralized rapid RNA diagnostic solutions, marking an end to its efforts in the Health Tech & Life Sciences market.
Log in to access full profile ›Company Intelligence Q&A
- What is NAOR's primary focus?
- NAOR focuses on developing decentralized rapid RNA diagnostic solutions for pathogens such as COVID-19, utilizing a one-step nucleic acid amplification method.
- When was NAOR founded?
- NAOR was founded in July 2020.
- What is the current operational status of NAOR?
- NAOR ceased operations in March 2024.
- What technology underpins NAOR's diagnostic platform?
- NAOR's technology integrates biochemistry, electronics, and artificial intelligence to achieve high sensitivity and specificity in its rapid RNA diagnostic platform.